Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9115

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Interventions: Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 344
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more

Conditions: Psoriatic Arthritis (PsA)
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 55
States / cities: Anniston, Alabama • Fullerton, California • Huntington Beach, California + 50 more

Conditions: Heart Failure
Interventions: vicadrostat, empagliflozin, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 94
States / cities: Mobile, Alabama • Chula Vista, California • Orange, California + 81 more

Conditions: Chronic Pruritus of Unknown Origin
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Tampa, Florida • Sandy Springs, Georgia • Brighton, Massachusetts + 5 more

Conditions: Arthroplasty, Replacement
Interventions: Investigational Arm: SMR Stemless Reverse, Control Arm: SMR Reverse Shoulder System; Device
Lead sponsor: Limacorporate S.p.a; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • Boca Raton, Florida + 9 more

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 38
States / cities: San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more

Conditions: Systemic Lupus Erythematosus
Interventions: BI 3000202, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 30
States / cities: Beverly Hills, California • La Palma, California • San Diego, California + 27 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Laguna Hills, California • Palo Alto, California + 39 more

Conditions: Atrial Fibrillation
Interventions: PulseSelect™ PFA system; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 19
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Lumbar Spinal Stenosis
Interventions: MILD, Interspinous Process Decompression; Device
Lead sponsor: Stryker Instruments; Industry
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2384
States / cities: Athens, Alabama • Bay Minette, Alabama • Birmingham, Alabama + 1286 more

Conditions: Parkinson Disease
Interventions: AP-472, Placebo; Drug · Other
Lead sponsor: Appello Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more

Conditions: Generalized Myasthenia Gravis
Interventions: Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 19
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

SMR Stemless Reverse vs SMR Reverse Shoulder System

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

PULSED AF Post-Approval Study

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis